Mark Klempner to Receptors, Tumor Necrosis Factor, Type II
This is a "connection" page, showing publications Mark Klempner has written about Receptors, Tumor Necrosis Factor, Type II.
Connection Strength
0.009
-
Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol. 1997 Mar; 15(3):1052-62.
Score: 0.009